Key Trial Data A randomized controlled trial by Mooren et al
discuss any supplement use with your clinical team If you are taking other prescribed medicines , particularly those with a narrow therapeutic index, as delayed gastric emptying associated with GLP-1 therapies may affect their absorption Seek urgent medical attention contact NHS 111 or go to an urgent care centre if you experience any of the following whilst taking a GLP-1-based medicine: Severe or persistent abdominal pain (which may rarely indicate pancreatitis or gallbladder disease) Persistent vomiting or inability to keep fluids down, which can lead to dehydration Symptoms of hypoglycaemia (shakiness, sweating, confusion, or palpitations), particularly if you are also taking insulin or a sulfonylurea A pharmacist is an accessible first point of contact for supplement-related queries and can advise on potential interactions, product quality, and appropriate dosing
Indianapolis: Eli Lilly (2026)
Delivering tapering strategies for long-term sustainability
Low adherence to this diet was associated with the development of atrial fibrillation, and high adherence with spontaneous conversion back to normal electrical impulses in the heart
Wegovy has been approved by the FDA to reduce risk of major adverse cardiovascular events (MACE) in those with a history of MACE, but studies of Zepbound are still pending
